Alpha 2.0
Login Register
» Authors » Jon Armstrong

Jon Armstrong

Explore the profile of Jon Armstrong including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 2068
Followers 0
Related Specialties
Infectious Diseases
Oncology
General Medicine
Top 10 Co-Authors
Peter Iversen
Paul Newell
Timi Edeki
Shampa Das
Thomas Morris
Manfred P Wirth
Mustafa Ozguroglu
Leanne B Gasink
William A See
Haiyi Jiang
Published In
BJU Int
Clin Infect Dis
Lancet Infect Dis
Antimicrob Agents Chemother
Cancer Res Commun
Affiliations
Soon will be listed here.
Recent Articles
1.
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Powles T, Catto J, Galsky M, Al-Ahmadie H, Meeks J, Nishiyama H, et al.
N Engl J Med . 2024 Sep; 391(19):1773-1786. PMID: 39282910
Background: Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve outcomes. Methods: In this phase 3, open-label,...
2.
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study
Reinmuth N, Juan-Vidal O, Kowalski D, Bryl M, Kryzhanivska A, Vicente D, et al.
Clin Cancer Res . 2024 Jul; 30(18):4055-4067. PMID: 39017667
Purpose: The phase II, multiarm, signal-searching BALTIC study (NCT02937818) assessed novel treatment combinations for platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC). Patients And Methods: Patients with ES-SCLC with progressive disease...
3.
Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation
Wildsmith S, Ye J, Franks A, Melillo G, Armstrong J, Whiteley J, et al.
Cancer Res Commun . 2023 Mar; 2(1):39-48. PMID: 36860696
Significance: A novel algorithm for PD-L1 expression using the cut-off point TC ≥ 50%/IC ≥ 25% is robust for identifying patients with HNSCC most likely to benefit from durvalumab treatment...
4.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Goldman J, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al.
Lancet Oncol . 2020 Dec; 22(1):51-65. PMID: 33285097
Background: First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum-etoposide) showed a significant improvement in overall survival versus platinum-etoposide alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) in...
5.
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al.
Lancet . 2019 Oct; 394(10212):1929-1939. PMID: 31590988
Background: Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN trial...
6.
Ceftazidime-avibactam in ceftazidime-resistant infections
Carmeli Y, Armstrong J, Newell P, Stone G, Wardman A
Lancet Infect Dis . 2016 Sep; 16(9):997-998. PMID: 27684334
No abstract available.
7.
Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients
Bradley J, Armstrong J, Arrieta A, Bishai R, Das S, Delair S, et al.
Antimicrob Agents Chemother . 2016 Aug; 60(10):6252-9. PMID: 27503642
This study aimed to investigate the pharmacokinetics (PK), safety, and tolerability of a single dose of ceftazidime-avibactam in pediatric patients. A phase I, multicenter, open-label PK study was conducted in...
8.
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Wagenlehner F, Sobel J, Newell P, Armstrong J, Huang X, Stone G, et al.
Clin Infect Dis . 2016 Jun; 63(6):754-762. PMID: 27313268
Background: The global emergence of carbapenem-resistant Enterobacteriaceae highlights the urgent need to reduce carbapenem dependence. The phase 3 RECAPTURE program compared the efficacy and safety of ceftazidime-avibactam and doripenem in...
9.
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised,...
Carmeli Y, Armstrong J, Laud P, Newell P, Stone G, Wardman A, et al.
Lancet Infect Dis . 2016 Apr; 16(6):661-673. PMID: 27107460
Background: Carbapenems are frequently the last line of defence in serious infections due to multidrug-resistant Gram-negative bacteria, but their use is threatened by the growing prevalence of carbapenemase-producing pathogens. Ceftazidime-avibactam...
10.
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
Mazuski J, Gasink L, Armstrong J, Broadhurst H, Stone G, Rank D, et al.
Clin Infect Dis . 2016 Mar; 62(11):1380-1389. PMID: 26962078
Background: When combined with ceftazidime, the novel non-β-lactam β-lactamase inhibitor avibactam provides a carbapenem alternative against multidrug-resistant infections. Efficacy and safety of ceftazidime-avibactam plus metronidazole were compared with meropenem in...